The Trump administration seems like its leaning toward allowing unapproved peptides.
So says The Washington Post. I’ve been writing about gray-market peptides in Optimizer, but this is a follow-up to July’s FDA hearings about whether compounding pharmacies should be allowed to sell unapproved peptides. It’s unclear which ones, and the timing could change, but the Post says this might give the administration a “political upside.” [Link: Trump administration paving way for temporary sale of some unapproved peptides | https://www.washingtonpost.com/health/2026/10/07/trump-administration-paving-way-temporary-sale-some-unapproved-peptides/ | The Washington Post]
So says The Washington Post . I’ve been writing about gray-market peptides in Optimizer , but this is a follow-up to July’s FDA hearings about whether compounding pharmacies should be allowed to sell unapproved peptides. It’s unclear which ones, and the timing could change, but the Post says this might give the administration a “political upside.”
Sign in to see your notifications or create an account to join the conversation.
Gathered from external sources. Rights to this text belong to whoever originally published it.